Mersana Therapeutics (MRSN) Tops Q4 EPS by 5c

Mersana Therapeutics (NASDAQ: MRSN) reported Q4 EPS of ($0.44), $0.05 better than the analyst estimate of ($0.49). Revenue for the quarter came in at $14.69 million versus the consensus estimate of $15.28 million.

For earnings history and earnings-related data on Mersana Therapeutics (MRSN) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Eikon Therapeutics, Inc. (EIKN) Misses Q2 EPS by 163c
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance